Bausch Health Companies Inc. BHC
Bausch Health Companies Inc. (NYSE: BHC) is a GI/hepatology drug developer. Its lead program, Larsucosterol, is in Phase 3 for severe alcohol-associated hepatitis. Its next catalyst on record is Larsucosterol: registrational Phase 3 program ongoing for severe alcohol-associated hepatitis (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Larsucosterol — registrational Phase 3 program ongoing for severe alcohol-associated hepatitis (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Lumify next generation | ocular redness | small molecule | Approved |
| CABTREO | acne | small molecule | Approved |
| Clear + Brilliant Touch | skin resurfacing | device-combination | Approved |
| Fraxel FTX | skin resurfacing | device-combination | Approved |
| Lumify Preservative Free | ocular redness | small molecule | Approved |
| Blink NutriTears | dry eye | unclear | Approved |
| Blink Boost preservative-free | dry eye | unclear | Approved |
| Blink Triple Care preservative-free lipid | dry eye | unclear | Approved |
| LuxLife Trifocal IOL | cataract | device-combination | Approved |
| Larsucosterol | severe alcohol-associated hepatitis | small molecule | Phase 3 |
| enVista Beyond | extended depth of focus IOL | device-combination | Phase 3 |
| Amiselimod | mild to moderate ulcerative colitis | small molecule | Phase 2 |
Recent results and decisions
- Feb 18, 2026started Phase 3 trial of larsucosterol in alcohol-associated hepatitis initiated, first patient randomized in January 2026.
Initiated Phase 3 trial with the first patient randomized in January 2026
Filing - Jan 23, 2026missed Both RED-C Phase 3 trials did not achieve their primary endpoint, though safe and well-tolerated (top-line results first announced January 23, 2026).
While safe and well-tolerated, both clinical trials did not achieve their primary endpoint
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.